Revance proposes follow-on

Dermatology company Revance Therapeutics Inc. (NASDAQ:RVNC) proposed late Monday to sell 3 million shares in a follow-on. Cowen; Piper Jaffray; BMO Capital Markets; and William Blair are underwriters. If sold at Revance's Monday close of $29.64, the company would raise $88.9 million.

Revance's RT001, a topical botulinum neurotoxin type A, is in Phase III testing to treat canthal lines (crow's feet), with data expected next half. The company raised $96 million in an IPO in February. ...